Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-053466

Audentes Therapeutics, Inc. · BOLD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Matthew R Patterson
Officer — Chief Executive Officer · Director
Period of report
Oct 1, 2018
Accepted (ET)
Oct 2, 2018 · 7:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockOct 1, 2018M2,144$0.78A17,144D
Common StockF2Oct 1, 2018S2,144$39.135D15,000D
Common StockOct 1, 2018M5,330$0.78A20,330D
Common StockF3Oct 1, 2018S5,330$38.036D15,000D
Common StockOct 1, 2018M5,448$0.78A20,448D
Common StockF4Oct 1, 2018S5,448$38.576D15,000D
Common StockOct 1, 2018M8,078$0.78A23,078D
Common StockF5Oct 1, 2018S8,078$37.704D15,000D
Common StockF6holding———171,814IBy Matthew R. Patterson Revocable Trust

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F7$0.78Oct 1, 2018M21,000D—Sep 25, 2023Common Stock21,00071,702D

Explanation of responses